Immatics reported a loss of $86.3 million last quarter, but its revenue grew to $7.8 million.

Nov 10, 2026, 11:40 AM ETResultsRead the original at globenewswire.com

Neutral

Immatics' quarterly loss grew as SUPRAME trial costs rose, but sales also rose from milestone payments and collaboration work. The report gives no detailed IMA402 results, so these changes point in different directions.

IMTX · Immatics N.V.

AI read · Neutral

The AI's read

The added trial spending explains the larger loss, but the report does not say whether it produced better trial results. More milestone payments and collaboration work lifted sales, and Immatics reported progress with IMA402 without giving details. These facts point in different directions, so the update does not clearly change the company's outlook.

Get alerts for IMTX

Follow Immatics N.V. (IMTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMTX

Free on the App Store and Google Play, or on the web.